Results 41 to 50 of about 253,625 (250)

Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE)

Cancer
Radium‐223 and taxane chemotherapy each improve survival of patients with metastatic castration‐resistant prostate cancer (mCRPC). Whether the radium‐223–taxane sequence could extend survival without cumulative toxicity was explored.
Celestia S Higano, John Logue, Jeffrey J Tomaszewski   +2 more
exaly   +2 more sources

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer

Journal of Multidisciplinary Healthcare, 2015
Joseph F Renzulli II, Jennifer Collins, Anthony Mega Genitourinary Multidisciplinary Clinic, The Miriam Hospital, Providence, RI, USAAbstract: Improving options for patients with metastatic castration-resistant prostate cancer (mCRPC) provide latitude in
Renzulli II JF, Collins J, Mega A
doaj   +1 more source

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient. [PDF]

Front Oncol
Despite the development of new therapies in the last few years, metastatic prostate cancer (PCa) is still a lethal disease. Radium-223 (Ra-223) is approved for patients with advanced castration-resistant prostate cancer (CRPC) with bone metastases and no
Zacchi F, Carles J, Gonzalez M, Maldonado X, Perez-Lopez R, Semidey ME, Mateo J.   +6 more
europepmc   +2 more sources

Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan. [PDF]

J Chin Med Assoc
Background: Radium-223 dichloride (Ra-223) prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases. However, there is considerable variation in outcomes among individuals.
Yao SF, Huang WJ, Wei TC, Wang YF, Lin KH, Hu LH, Ting CH, Lee TH, Yeh SH, Peng NJ.   +9 more
europepmc   +2 more sources

Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report

Frontiers in Oncology, 2022
Radium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer.
Hélène Houssiau, Francois P. Duhoux, Didier François, Emmanuel Seront   +3 more
doaj   +1 more source

Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan

Journal of the Formosan Medical Association, 2022
Background: Radium-223 is an alpha-emitting, bone-targeting radiopharmaceutical that confers a survival benefit in patients with confirmed bone-metastatic, castration-resistant prostate cancer with no visceral metastases.
Wei-Chun Weng, Li-Hua Huang, Neng-Chuan Tseng, Yen-Chuan Ou   +3 more
doaj   +1 more source

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study

Cancer Medicine, 2023
Background Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in ...
Anniina Hyväkkä, Okko‐Sakari Kääriäinen, Tapio Utriainen, Eliisa Löyttyniemi, Kalle Mattila, Petri Reinikainen, Jorma Sormunen, Minna Jääskeläinen, Päivi Auvinen, Heikki Minn, Maria Sundvall   +10 more
doaj   +1 more source

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis

Frontiers in Pharmacology, 2022
Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China.Materials and methods: A Markov model was developed to estimate the long-term health and economic ...
Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma   +5 more
doaj   +1 more source

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report

Urology Case Reports, 2020
Radium-223 is used for treating castration-resistant prostate cancer with bone metastases. Here, we report the case of a 76-year-old man diagnosed with castration-resistant prostate cancer with bone metastases who was started on radium-223.
Masato Dobashi, Dai Kouguchi, Yukiko Kanetsuna, Junichiro Ishii   +3 more
doaj   +1 more source

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer

Journal of the Formosan Medical Association, 2017
Radium-223 is a first-in-class α-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC).
Tai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, Chao-Yuan Huang, Shu-Pin Huang, Chia-Chi Lin, Yen-Chuan Ou, See-Tong Pang, Daniel Heung-Yuan Shen, Wen-Jeng Wu, Wayne Yen-Hwa Chang   +10 more
doaj   +1 more source